CAR T-cell therapy in autoimmune diseases
Schett G, Mackensen A, Mougiakakos D (2023)
Publication Type: Journal article, Review article
Publication year: 2023
Journal
DOI: 10.1016/S0140-6736(23)01126-1
Abstract
Despite the tremendous progress in the clinical management of autoimmune diseases, many patients do not respond to the currently used treatments. Autoreactive B cells play a key role in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis. B-cell-depleting monoclonal antibodies, such as rituximab, have poor therapeutic efficacy in autoimmune diseases, mainly due to the persistence of autoreactive B cells in lymphatic organs and inflamed tissues. The adoptive transfer of T cells engineered to target tumour cells via chimeric antigen receptors (CARs) has emerged as an effective treatment modality in B-cell malignancies. In the last 2 years treatment with autologous CAR T cells directed against the CD19 antigen has been introduced in therapy of autoimmune disease. CD19 CAR T cells induced a rapid and sustained depletion of circulating B cells, as well as in a complete clinical and serological remission of refractory systemic lupus erythematosus and dermatomyositis. In this paper, we discuss the evolving strategies for targeting autoreactive B cells via CAR T cells, which might be used for targeted therapy in autoimmune diseases.
Authors with CRIS profile
Involved external institutions
Germany (DE)How to cite
APA:
Schett, G., Mackensen, A., & Mougiakakos, D. (2023). CAR T-cell therapy in autoimmune diseases. The Lancet. https://doi.org/10.1016/S0140-6736(23)01126-1
MLA:
Schett, Georg, Andreas Mackensen, and Dimitrios Mougiakakos. "CAR T-cell therapy in autoimmune diseases." The Lancet (2023).
BibTeX: Download